YU1203A - Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca - Google Patents

Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca

Info

Publication number
YU1203A
YU1203A YU1203A YUP1203A YU1203A YU 1203 A YU1203 A YU 1203A YU 1203 A YU1203 A YU 1203A YU P1203 A YUP1203 A YU P1203A YU 1203 A YU1203 A YU 1203A
Authority
YU
Yugoslavia
Prior art keywords
insulin resistance
treatment
cardiac insulin
prevention
cardiac
Prior art date
Application number
YU1203A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of YU1203A publication Critical patent/YU1203A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YU1203A 2000-06-16 2000-06-16 Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca YU1203A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
YU1203A true YU1203A (sh) 2006-05-25

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1203A YU1203A (sh) 2000-06-16 2000-06-16 Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca

Country Status (15)

Country Link
EP (1) EP1292301A1 (hu)
JP (1) JP2004503499A (hu)
CN (1) CN1592620A (hu)
AP (1) AP2002002688A0 (hu)
BG (1) BG107384A (hu)
BR (1) BR0017254A (hu)
CA (1) CA2436116A1 (hu)
DZ (1) DZ3389A1 (hu)
EA (1) EA200300028A1 (hu)
HU (1) HUP0301103A2 (hu)
IL (1) IL153452A0 (hu)
MX (1) MXPA02012619A (hu)
NO (1) NO20026000L (hu)
WO (1) WO2001095906A1 (hu)
YU (1) YU1203A (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
NO20026000L (no) 2003-02-11
MXPA02012619A (es) 2003-04-10
IL153452A0 (en) 2003-07-06
WO2001095906A1 (en) 2001-12-20
CA2436116A1 (en) 2001-12-20
CN1592620A (zh) 2005-03-09
AP2002002688A0 (en) 2002-12-31
EA200300028A1 (ru) 2003-04-24
EP1292301A1 (en) 2003-03-19
HUP0301103A2 (hu) 2003-08-28
DZ3389A1 (fr) 2001-12-20
NO20026000D0 (no) 2002-12-13
BR0017254A (pt) 2004-01-06
JP2004503499A (ja) 2004-02-05
BG107384A (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
Al Zuhair et al. Pumpkin-seed oil modulates the effect of felodipine and captopril in spontaneously hypertensive rats
NL300282I1 (nl) Nieuwe exendineagonistformuleringen en werkwijze voor toediening daarvan.
AR093609A2 (es) Compuesto amorfo de benzimidazol, composicion farmaceutica que lo comprende y metodo para tratar o prevenir la ulcera gastrica
WO2008142627A3 (en) Multilayered modified release formulation comprising amoxicillin and clavulanate
WO2002100433A1 (en) Medicinal compositions
WO2003080566A3 (en) Hif hydroxylase inhibitors
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
WO2000062766A3 (en) Uses of ppar-gamma agonists in neutrophil-induced diseases
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
MX9805512A (es) Un aparato para colocacion de escuadra en salientes de conducto de ventilacion.
EP1602645A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
YU1203A (sh) Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca
AU2000258410A1 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2004043229A3 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
WO2008051902A3 (en) Method of restoring the incretin effect
WO2009073146A3 (en) Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2005016269A3 (en) Methods for treating metabolic syndrome
WO2006055573A3 (en) Methods of using pde v inhibitors for the treatment of congestive heart failure